A study to evaluate patients with early-stage or locally advanced HER2-positive breast cancer who received pertuzumab plus docetaxel and trastuzumab (neoadjuvant therapy) before surgery and pertuzumab plus trastuzumab after postoperative chemotherapy.
| Title | A study to evaluate patients with early-stage or locally advanced HER2-positive breast cancer who received pertuzumab plus docetaxel and trastuzumab (neoadjuvant therapy) before surgery and pertuzumab plus trastuzumab after postoperative chemotherapy. |
|---|---|
| Description | One study evaluated patients with early-stage or locally advanced HER2-positive breast cancer who received pertuzumab plus docetaxel, trastuzumab (neoadjuvant therapy) before surgery, and pertuzumab plus trastuzumab after postoperative chemotherapy. Publish the data of the randomized, multi-center, double-blind, placebo-controlled phase III study of zizumab (adjuvant therapy), including HER2 FISH, HER2/3 mRNA and PIK3CA report data, and does not involve sequencing |
| Organism | Homo sapiens |
| Data Type | Biomarker Data |
| Data Accessibility | Controlled-access |
| BioProject | PRJCA021885 |
| Release Date | 2023-12-16 |
| Submitter | Lanyun Xiang (lanyun.xiang@tigermedgrp.com) |
| Organization | Hangzhong Tigermed Consulting Co., Ltd. |
| Submission Date | 2023-12-08 |
HTTP download speed may be slow. It is highly recommended that you download the dataset using a dedicated FTP tool (such as FileZilla Client).
| File ID | File Title | Number/Samples | File Type | File Size | File Suffix | Download Times | Download |
|---|---|---|---|---|---|---|---|
| OMIX005356-01 | HER2 FISH, HER2/3 mRNA and PIK3CA report data | 216 | Biomarker Data | 289.7 KB | xlsx | 0 | Controlled |